Table 3.

Adjusted rates of clinical outcomes per 1000 person-years in strata defined by eGFR and urinary ACR

eGFR (ml/min per 1.73 m2)OutcomePVDPCI or CABGCHFCVA/TIA
Normal ACRMild ACRHeavy ACROverallNormal ACRMild ACRHeavy ACROverallNormal ACRMild ACRHeavy ACROverallNormal ACRMild ACRHeavy ACROverall
≥60Events (n)1314912192109636598155928123811062940518763655
People in cell (n)64, 14614, 597280581, 54864, 14614, 597280581, 54864, 14614, 597280581, 54864, 14614, 597280581, 548
Adjusted rate0.50.60.80.55.06.18.25.31.12.65.51.51.82.74.72.1
95% CI0.4 to 0.60.4 to 0.80.4 to 1.40.4 to 0.64.7 to 5.45.5 to 6.86.7 to 10.05.0 to 5.60.9 to 1.22.2 to 3.04.4 to 6.71.4 to 1.71.6 to 2.02.3 to 3.23.6 to 6.11.9 to 2.3
45 to 59.9Events (n)622612100278117564511741868844814910548302
People in cell (n)10, 3163520112614, 96210, 3163520112614, 96210, 3163520112614, 96210, 3163520112614, 962
Adjusted rate0.70.71.00.75.66.09.05.91.63.65.82.21.93.25.12.4
95% CI0.5 to 0.90.4 to 1.10.6 to 1.90.5 to 0.94.9 to 6.44.9 to 7.26.9 to 11.85.3 to 6.51.3 to 1.93.0 to 4.44.6 to 7.31.9 to 2.61.6 to 2.32.6 to 4.03.7 to 6.92.1 to 2.7
30 to 44.9Events (n)252375586573517810512897330765033159
People in cell (n)247416248374935247416248374935247416248374935247416248374935
Adjusted rate0.81.00.70.86.76.47.56.52.44.16.93.12.92.84.12.8
95% CI0.5 to 1.20.6 to 1.70.3 to 1.50.6 to 1.25.4 to 8.44.8 to 8.45.4 to 10.75.6 to 7.82.0 to 3.13.3 to 5.05.5 to 8.82.6 to 3.62.2 to 3.72.0 to 3.82.8 to 5.92.3 to 3.4
15 to 29.9Events (n)389209813303762491489161641
People in cell (n)3444764361256344476436125634447643612563444764361256
Adjusted rate0.61.42.41.45.63.66.14.84.86.56.24.62.53.33.92.9
95% CI0.2 to 2.00.7 to 3.11.2 to 4.90.8 to 2.32.9 to 10.81.8 to 7.23.5 to 10.73.3 to 7.03.4 to 6.84.8 to 8.74.5 to 8.63.7 to 5.71.2 to 4.81.9 to 5.52.3 to 6.72.0 to 4.1
  • Adjusted for age; gender; diabetes; hypertension; socioeconomic status; and history of cancer, cerebrovascular disease, CHF, chronic pulmonary disease, dementia, diabetes with end-organ damage, diabetes without chronic complication, AIDS/HIV, metastatic solid tumor, myocardial infarction, mild liver disease, moderate or severe liver disease, paralysis, peptic ulcer disease, PVD, renal disease, or rheumatic disease. In this analysis, only urinary ACR was used to classify participants with respect to proteinuria: normal (ACR < 30 mg/g), mild (ACR 30 to 300 mg/g), or heavy (ACR > 300 mg/g). n = 102,701 The tests for linear trend across proteinuria categories were all significant at the P < 0.001 level except for PVD (P = 0.15). Tests for trend across eGFR categories were PVD, P = 0.01; PCI or CABG, P = 0.01; CHF, P < 0.001; and CVA/TIA, P < 0.007.